Biotechnology News

Multiple Myeloma - 85% overall response rate (71% CR/sCR) for NXC-201 at therapeutic dose in an ongoing Phase 1b study in 20 relapsed/refractory patients as of June 27, 2022 data cutoff...

Funding will support the final development phase prior to planned 2023 FDA submission of the company’s “breakthrough” designated eNOcare™ hospital device WALTHAM, Mass., Dec. 14, 2022 (GLOBE...

– IgA protease candidate in combination with ImmTOR further enhances pipeline – – Novel mechanism of action of IgA protease has the potential to address the underlying kidney pathophysiology of IgA...

Update Offers More Comprehensive Understanding of PaxMedica’s Focus, Process and Progress Tarrytown, NY, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a...

VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter...

BURLINGTON, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...

Kill Cliff FC is One of the world’s largest MMA Training Centers with More Than 80 Professional Fighters POMPANO BEACH, FLORIDA., Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC:...

SEATTLE, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with...

BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...

Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology Third product company from Replay expands use of next-generation high payload...